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Despite a blood-brain barrier for norepinephrine, the concentration of norepinephrine in plasma and cerebrospinal fluid has been 
observed to be similar. This relationship between plasma and cerebrospinal fluid norepinephrine levels suggests that peripheral sym- 
pathetic neurons innervating blood vessels to brain and spinal cord may contribute significantly to cerebrospinal fluid norepinephrine 
levels, and questions the validity of cerebrospinal fluid norepinephrine as an index of central nervous system noradrenergic activity. 
We demonstrate that extensive destruction of the peripheral sympathetic nervous system and the adrenal medulla has no effect on rat 
cerebrospinal fluid norepinephrine. It is therefore unlikely that peripheral sources of norepinephrine contribute significantly to cere- 
brospinal fluid norepinephrine levels. 
INTRODUCTION 
Cerebrospinal  fluid (CSF) norepinephr ine  (NE) 
concentrat ion has been used as an index of central 
nervous system (CNS) noradrenergic  activity in stud- 
ies of  such diseases as hyper tension 19, schizophre- 
nia 20, depression 31, amyotrophic  lateral  sclerosis 39, 
and Alzheimer ' s  disease 32. The assumption that CSF 
NE is a valid measure  of brain noradrenergic  activity 
is based upon several  factors. Noradrenergic  cell 
bodies in the locus coeruleus and rostral ly project ing 
subcoeruleus nuclei provide a part icular ly rich nor- 
adrenergic innervat ion to brain areas in close prox- 
imity to the CSF and caudally project ing noradrener-  
gic nuclei also innervate the spinal cord25, 35. Also,  
norepinephrine  injected into the CSF is taken up by 
catecholaminergic neurons of central  ra ther  than pe- 
ripheral  origin 8. In addit ion,  an effective b l o o d -  
brain barr ier  for NE has been well documented4L 
However ,  despite this b l o o d - b r a i n  barr ier  for NE,  
there is a close correlat ion between NE in CSF and 
plasma when the two compar tments  are sampled si- 
multaneously 32.40. Because plasma NE reflects pe- 
r ipheral  sympathet ic  nervous system (SNS) activ- 
ity 17, the close relat ionship between CSF and plasma 
NE suggests that e i ther  NE release in both compart -  
ments is joint ly regula ted,  or  that  the per iphera l  SNS 
somehow contr ibutes  significantly to CSF NE levels 
as well as to p lasma NE levels. If the per iphera l  SNS 
does contr ibute significantly to CSF NE,  the validity 
of CSF NE as an index of CNS noradrenerg ic  activity 
is suspect. 
We investigated the contr ibut ion of the per ipheral  
SNS to CSF NE levels by measur ing CSF NE follow- 
ing chemical abla t ion of the SNS and adrenal  medul -  
lectomy. Chronic adminis t ra t ion of guanethidine to 
neonatal  rats produces  per iphera l  sympathec tomy 
but spares central  noradrenergic  neurons and the 
adrenal  medul la  15. In this study, we measured CSF 
and plasma NE concentrat ions  in guanethidine-sym- 
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pathectomized rats, guanethidine-sympathecto- 
mized/adrenal medullectomized rats, and sham- 
injected/sham-operated control rats. Measurements 
of plasma NE following decapitation and tissue NE 
content in hypothalamus, cerebral cortex, heart, and 
adrenals provided indices of the effectiveness of the 
guanethidine sympathectomy and adrenal medullec- 
tomy procedures. In addition, we measured CSF and 
plasma epinephrine (E) concentrations and adrenal 
E content in the 3 groups. 
MATERIALS AND METHODS 
Chemical sympathectomy was performed in 40 
male Sprague-Dawley rats beginning at one week of 
age by administering 5 daily subcutaneous injections 
of 50 mg/kg guanethidine monosulfate (Ciba Geigy) 
dissolved in 10/~l/g body weight of normal saline per 
week for 3 weeks 15. Sixteen littermates received an 
identical course of normal saline. All rats were 
weaned at 4 weeks of age and housed 2 to a cage with 
free access to standard laboratory rat chow and tap 
water. 
At age 7 weeks, guanethidine-treated rats under- 
went either bilateral enucleation of the adrenal 
gland 38 or sham surgery. All control rats underwent 
sham surgery. The adrenal cortex but not the adrenal 
medulla regenerates after adrenal enucleation, thus 
producing a functionally adrenal medullectomized 
animal13, 34. Adrenal medullectomy took place under 
ether anesthesia. A single midline dorsal skin incision 
was made and the lateral abdominal wall parted on 
each side to expose the adrenals. Each adrenal was 
carefully lifted, a small incision made in the capsule 
with microscissors, and the body of the gland ex- 
truded with blunt forceps. The skin incision was 
closed with wound clips. The sham operation consis- 
ted of the above procedure through exposure of the 
adrenal capsule followed by closure of the skin inci- 
sion. Operated rats received 0.9% saline in place of 
tap water to drink for the first 7 days following sur- 
gery and then a choice of saline or tap water for an 
additional 7 days 38. Saline was provided to compen- 
sate for salt and water losses during the period of cor- 
ticosteroid deficiency. Sham-operated rats received 
only tap water to drink. 
At the end of the study, control rats weighed signif- 
icantly more (394 + 9 g) than either sympathecto- 
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mized (330 + 9 g) or sympathectomized/adrenal 
medullectomized (327 _+ 10 g) r a t s  (F2,38 = 16.66, 
P < 0.001). Sympathectomized rats developed 
marked ptosis which persisted for the duration of the 
study. Fifteen sympathectomized rat pups but no 
control group rat pups died at some point during the 
study. 
At 12 weeks of age, CSF and tail vein samples were 
collected under ketamine anesthesia (100 mg/kg 
i.p.). Ketamine does not affect baseline plasma cate- 
cholamine concentrations in primates4,16. After nick- 
ing the tail vein, 200/4 of blood were collected into 
iced tubes containing heparin and reduced gluta- 
thione. Immediately following tail vein sampling, ap- 
proximately 150/~1 of CSF were collected from the 
cisterna magna 36. The rat was mounted on a stereo- 
taxic device modified to position the head at a 90 ° an- 
gle to the body. The location of the cisterna magna 
was estimated by setting the dorsal-ventral drive of 
the stereotaxic 6.8 mm below the top of the skull. A 
30-gauge needle attached to PE 10 polyethylene tub- 
ing was advanced through a small skin incision into 
the cisterna and the CSF was allowed to flow by grav- 
ity into iced tubes containing reduced glutathione. 
After fully awakening from anesthesia (15-20 
min), the rats were decapitated and trunk blood col- 
lected into tubes containing iced heparin and reduced 
glutathione. Decapitation of unanesthetized rats pro- 
duces a 10-fold increase in trunk blood NE and E lev- 
els 3°. The brain was rapidly dissected on an iced glass 
plate and the hypothalamus and cerebral cortex 
blotted dry, weighed and frozen on dry ice. Hearts 
and adrenal glands also were rapidly removed, rinsed 
with iced saline, blotted dry, weighed and frozen on 
dry ice. All CSF, plasma and tissue samples were 
stored at -70 °C. 
CSF and plasma NE and E levels were determined 
by a sensitive radioenzymatic methodS,29. Tissue NE 
and E levels were determined by reverse-phase high- 
performance liquid chromatography (HPLC) with 
electrochemical detection. 
Adrenal (40 + 2 mg) and hypothalamic (59 + 3 
mg) samples were homogenized by sonication (Bran- 
son Cell Disrupter 200) in 1.0 ml cold 0.1 N HC104. 
Cortex samples (0.51 + 0.02 g) were similarly ho- 
mogenized in 4.0 ml perchloric acid. Heart samples 
(1.10 + 0.03 g) were Polytron (Brinkmann) homoge- 
nized in 15 ml HCIO 4 prior to sonication. Samples 
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were centrifuged at 25,000 g for 20 min at 4 °C and 
the supernatant was removed and stored at -70 °C: 
10 ktg of 3,4-dihydroxybenzylamine (DHBA) was 
added as an internal standard to 0.80 ml of the super- 
natant from control and sympathectomized rat 
adrenal extracts, and 200 ng was added to the same 
volume of medullectomized adrenal extracts. Acid- 
prepared alumina (200 mg) and 0.5 M Tris/2% 
EDTA, pH 8.6, buffer (1.5 ml) were added to each 
thawed adrenal extract. Each sample was mixed for 
15 min, centrifuged, and the supernatant discarded. 
The alumina was washed 3 times with 2.0 ml distilled 
water and the catecholamines eluted from the alumi- 
na with 1.0 ml 0.1 NHC10 4. Medullectomized adren- 
al extracts were used undiluted for HPLC, and con- 
trol and sympathectomized rat adrenal extracts were 
diluted 1:100 in 0.1 N HC10 4. Extraction of other tis- 
sues was identical except for quantities of standard 
and reagents. For hypothalamus, 100 ng DHBA, 50 
mg alumina, and 1.0 ml Tris buffer were added to 
0.85 mt of the homogenization supernatant. Cate- 
cholamines were eluted with 0.4 ml 0.1 N HC10 4 and 
diluted 1:3 for HPLC. For cortex, 200 ng DHBA, 50 
mg alumina, and 4.0 ml Tris buffer were added to the 
supernatant. Catecholamines were eluted with 0.4 ml 
0.1 N HC104 and diluted 1:40. For heart, 200 ng 
DHBA, 200 mg alumina, and 15 ml Tris buffer were 
added to the total supernatant. Catecholamines were 
eluted with 0.8 ml 0.1 N HCIO4; approximately half 
of the samples were diluted 1:4 for HPLC and the 
rest were undiluted. HPLC injection volume for all 
extracts was 10ktl. 
A Varian 5060 high-pressure liquid chromato- 
graph with Varian MCH-5 30 cm x 4 mm reverse- 
phase column was used for catecholamine separa- 
tion. The mobile phase consisted of 0.1 M sodium 
acetate, 0.02 M citric acid, 10 rag/1 1-octanesulfonic 
acid (sodium salt monohydrate), 50 mg/1 sodium 
EDTA and 10% methanol. The flow rate was 1,0 
ml/min. Detection was accomplished using a TL-5 
glass carbon electrode and LC-17 flow cell (Bioanaly- 
tical Systems) and amperometric detector (LC-4A, 
Bioanalytical Systems) with an applied potential of 
+0.65 V vs Ag/AgC1. 
A 0.1 N HC104 solution containing 20 ng/ml each 
of norepinephrine bitartrate, epinephrine, dopa- 
mine, and DHBA hydrobromide was injected on to 
the HPLC column in variable volumes (10-50 ~1) to 
yield standards of 0.2-1.0 ng. Peak heights were 
measured on the chromatographic chart recording 
and a linear standard curve prepared for each stand- 
ard. Extraction efficiency was calculated for each 
sample by determining the concentration of DHBA 
recovered and correcting the measured values for 
norepinephrine and epinephrine accordinglyg.24. Ex- 
traction efficiencies for each tissue were: adrenal, 
77.6 + 0.8%; hypothalamus, 87.7 _+ 1.5%: cortex, 
82.1 _ 0.6%; heart, 54.1 + 1.0%. 
RESULTS 
NE levels in CSF, tail vein plasma and post-decapi- 
tation plasma are shown in Fig. 1. In control animals, 
tail vein NE levels were similar to CSF NE levels. 
Tail vein plasma NE levels were reduced to 33% of 
control levels in the sympathectomized rats and 39% 
of control levels in sympathectomized/adrenal me- 
dullectomized r a t s  (/72,38 = 25.08, P < 0.001). How- 
ever, despite the marked reduction of tail vein plas- 
ma NE in sympathectomized rats, CSF NE did not 
differ between sympathectomized rats and controls 
(F2,38 = 0.74, P = n.s.). 
The effectiveness of sympathectomy and adrenal 
medullectomy was demonstrated by postdecapita- 
tion NE levels, which were reduced to 46% of control 
values in sympathectomized rats and 17% of control 
values in sympathectomized/adrenal medullecto- 
mized rats (F2,38 = 37.77, P < 0.001). The effective- 
ness of these procedures was further supported by 
the tissue catecholamine levels (Tables I and II). 
Heart NE content was markedly reduced to 2% of 
control content in sympathectomized rats and 4% of 
control content in sympathectomized/adrenal medul- 
lectomized rats (F2.38 = 523.02, P < 0.001). Adrenal 
NE and E content in sympathectomized/adrenal 
medullectomized rats were reduced to 2% of control 
c o n t e n t  (Fz ,3s  = 147.26, P < 0.001, and /~2.3~ = 
207.20, P < 0.001, respectively). Guanethidine sym- 
pathectomy spared CNS noradrenergic neurons as 
demonstrated by the absence of differences in hypo- 
thalamic NE content (F2.38 = 2.33, P = n.s.) and ce- 
rebral cortex NE content (F2.3s = 0.13, P = n.s.) 
among groups. Guanethidine sympathectomy also 
spared the adrenal medulla; in fact, adrenal NE was 
significantly higher in sympathectomized rats than in 
controls. 
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Fig. 1. Norepinephrine (NE) levels (pg/ml) in cerebrospinal 
fluid, tail vein plasma, and postdecapitation plasma in guane- 
thidine-sympathectomized rats (Syrup X), guanethidine sym- 
pathectomized and adrenal medullectomized rats (Syrup 
X/Med X), and control rats. Values are means + S.E.M. * P < 
0.001 compared to control group; ** P < 0.001 compared to 
Symp X and control groups; analysis of variance followed by 
Scheffe's test. 
E levels in CSF, tail vein plasma and postdecapita- 
tion plasma are presented in Table III. Tail vein plas- 
ma E levels are markedly higher than CSF E levels in 
all groups. Although tail vein plasma E tended to be 
lower in the sympathectomized/adrenal  medullecto- 
mized rats, this difference was not significant. Post- 
decapitation plasma E was markedly lower in the 
sympathectomized/adrenal medullectomized rats 
than in the other two groups (F2,38 = 23.69, 
P < 0.001). 
DISCUSSION 
This study demonstrates that extensive destruction 
TABLE I 
Norepinephrine levels (ng/g tissue) in hypothalamus, cortex and 
heart 
Values are means + S.E.M. Symp X, guanethidine sympathec- 
tomized rats; symp X/Med X, guanethidine sympathectom- 
ized/adrenal medullectomized rats. 
Group Hypo- Cortex Heart 
thalamus 
Control (n = 16) 1473 + 63 232 + 7 917 + 33 
Symp X (n = 13) 1456 + 70 238 + 9 21 + 6* 
Symp X/Med X 
(n = 12) 1288 + 66 238 + 10 34 + 12" 
* P < 0.001 compared to control group (analysis of variance 
followed by Scheffe's test). 
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TABLE II 
Norepinephrine (NE) (ng/g tissue) and epinephrine (E) (ng/g 
tissue) in whole adrenal gland 
Values are means + S.E.M. Symp X, guanethidine sympathec- 
tomized rats; Syrup X/Med X, guanethidine sympathectom- 
ized/adrenal meduilectomized rats. 
Group NE E 
Control (n = 16) 210 + 1 800 + 33 
Symp X (n = 13) 279 + 15" 870 + 40 
Symp X/Med X 
(n= 12) 4 + 2** 19 + 10"* 
* P < 0.001 compared to control group 
** P < 0.001 compared to control and Symp X groups. Statis- 
tical comparison is by analysis of variance followed by Scheffe's 
test. 
of the peripheral SNS does not affect CSF or brain 
NE levels in rats. Evidence for extensive destruction 
of peripheral SNS neurons includes the marked re- 
duction in cardiac NE content.  In addition, plasma 
NE levels, which appear to reflect NE spillover from 
sympathetic neurons innervating blood vessels 17, 
were considerably lower in sympathectomized ani- 
mals both in tail vein samples and after the stress of 
decapitation. Despite this evidence of extensive de- 
struction of peripheral SNS neurons,  sympathectomy 
had no effect on brain NE content  and CSF NE levels 
were unaltered. 
Our results support previous findings that guane- 
thidine sympathectomy produces an extensive and 
long-lasting sympathectomy, while sparing central 
noradrenergic neurons and the adrenal medulla.  
Heart NE levels were consistent with previous stud- 
ies which reported profound reductions in cardiac 
TABLE III 
Epinephrine (pg/ml) in cerebrospinal fluid and plasma 
Values are means + S.E.M. Symp X, guanethidine sympathec- 
tomized rats; Symp X/Med X, guanethidine sympathectom- 
ized/adrenal medullectomized rats. 
Group CSF Tail vein Postdecapi- 
plasma tation plasma 
Control 
(n = 16) 70 + 5 924 + 155 7841 + 1007 
Symp X 
(n = 13) 92 + 10 658 + 113 5554 + 748 
Symp X/Med X 
(n = 12) 71 + 11 548 + 95 166 + 46* 
* P < 0.001 compared to control and Symp X groups (analysis 
of variance followed by Scheffe's test). 
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NE content to between 2% and 22% of control 
values L2,7,10,15,21 following various protocols for gua~ 
nethidine treatment in neonatal and adult rats. Our 
finding of unchanged hypothalamic and cerebral cor- 
tical NE content in guanethidine-treated rats is con- 
sistent with the reports of Johnson et al. 14,15 who 
found no differences in NE content in whole brain, 
spinal cord, or cerebellum in guanethidine-treated 
neonatal and adult rats as compared to controls. 
A possible mechanism by which the peripheral 
SNS could contribute to CSF NE is via SNS neurons 
which innervate blood vessels to brain and spinal 
cord areas adjacent to the cerebral ventricles and the 
subarachnoid space. A prominent peripheral SNS in- 
nervation which degenerates following bilateral su- 
perior cervical ganglionectomy has been described in 
the choroid plexus and pial blood vessels of the rat 
and the pial vasculature of the cat 6,11,22.26. Fibers with 
typical catecholamine fluorescence closely asso- 
ciated with blood vessels in the subarachnoid space 
and pia have been described below the level of spinal 
cord transection in the chronic spinal rat and dog 23. 
Because chronic administration of guanethidine to 
neonatal rats produces peripheral sympathectomy 
with essentially complete destruction of the superior 
cervical ganglion as documented by electron micro- 
scopy3.12 it is unlikely that SNS neurons innervating 
CNS blood vessels contributed to CSF NE in our 
sympathectomized rats. 
Our finding of increased NE content in the adrenal 
glands of guanethidine-sympathectomized rats is 
consistent with that of Kvetnansky et al.~L who 
found adrenal NE content elevated to 170% of con- 
trol levels in their guanethidine-treated adult rats. 
Presumably, the increase of NE content represents a 
compensatory response of the adrenal medulla to de- 
struction of sympathetic neurons. Their finding of 
profoundly reduced adrenal NE levels in guanethi- 
dine-sympathectomized/adrenal medullectomized 
rats was also similar to our results. 
Tail vein plasma NE levels in our control rats were 
higher than those reported in unstressed, unanesthe- 
tized rats (from which blood samples were collected 
via an indwelling cannula), but were approximately 
midway between the levels reported in cannula blood 
from gently handled rats and rats subjected to immo- 
bilization stress 30. The high tail vein NE levels in our 
control rats occurred despite the use of ketamine an- 
esthesia, which has been reported to abolish the cate- 
cholamine response to acute cold exposure in mon- 
keys 16. It appears that the amount of ketamine anes- 
thesia used in this study did not completely abolish 
the NE response to immobilization and tail incision 
involved in our blood sampling procedure. 
Decapitation produced increased NE levels in con- 
trol rats consistent with previously reported data in 
unanesthetized normal rats 30. Decapitation in guane- 
thidine-sympathectomized and guanethidine-sympa- 
thectomized/adrenal medullectomized rats produced 
plasma NE levels considerably lower than those in 
control rats, but higher than previously reported dur- 
ing immobilization stress in guanethidine-sympa- 
thectomized and guanethidine-sympathectomized/a- 
drenal medullectomized ratsJS. However, in normal 
unanesthetized rats, decapitation produces plasma 
NE levels approximately 3 times higher than immobi- 
lization. 
Guanethidine treatment produced a significant de- 
gree of mortality and growth deficit. Our guanethi- 
dine-treated rats exhibited an increased mortality 
with 15 of 40 treated rats dying during the study peri- 
od compared to zero of t6 control rats. Treated rats 
also showed a persistent an d significant growth defi- 
cit, amounting to 17% at 12 weeks of age. Johnson et 
al.aS, using the identical treatment protocol, reported 
an excess mortality of 9% in guanethidine-treated 
rats as compared to 13% mortality in our treated rats 
not attributable to anesthesia or surgical procedures. 
They also reported a transient growth reduction of 
15% by the third week of treatment which disap- 
peared by 10-11 weeks of age. In an earlier study in- 
volving young adult ratsl4 and using a somewhat dif- 
ferent treatment protocol (40 mg/kg 5 days a week 
for 5 weeks), they reported a growth deficit in treated 
rats which was significant by 3 weeks of treatment 
and which persisted for at least 6 months. 
The large gradient between plasma E and CSF E 
supports the existence of a blood-brain barrier for 
catecholamines. This barrier has previously been 
demonstrated by radiolabeled catecholamine infu- 
sion studies in cats and primates27,33, 37, and by dem- 
onstration of a large gradient between CSF and plas- 
ma NE in a patient with pheochromocytoma, a NE- 
producing tumor of the adrenal medulla 41. This 
pheochromocytoma patient had an extremely high 
plasma NE concentration of 9680 pg/ml, but a simul- 
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taneously normal  CSF NE concentrat ion of  200 
pg/ml. 
The plasma E levels in the tail vein samples  from 
sympathectomized/adrenal  medul lec tomized  rats 
suggest secret ion of E by ext ra-adrenal  chromaffin 
tissue 2s in response to the tail vein nicking procedure .  
The decrease in plasma E levels after decapi ta t ion 
may result from an inabili ty to maintain stress-eleva- 
ted plasma levels or  to secrete enough E to elevate  
p lasma concentrat ions in response to a second stress 
within a short  per iod  of time. 
These results demons t ra te  that  extensive destruc- 
tion of per iphera l  SNS noradrenergic  neurons and 
the adrenal  medul la  has no effect on CSF or  brain 
levels of NE. It is highly unlikely that per iphera l  
sources of  NE contr ibute significantly to CSF NE.  
These results,  therefore,  s trengthen the validity of 
CSF NE levels as a measure  of CNS noradrenergic  
activity. It is speculated that the close relat ionship 
between CSF and plasma NE levels in humans is due 
to common control  mechanisms regulat ing noradren-  
ergic outflow in the CNS and per iphery ,  functionally 
linking central noradrenergic  systems and the periph-  
eral SNS. 
ACKNOWLEDGEMENTS 
We wish to thank David  Feder ighi  for technical as- 
sistance and Maxine Cormier  and Connie Evoy for 
secretarial  support .  This work  was suppor ted  in part  
by the Veterans  Adminis t ra t ion  and N I H  Grant  A G -  
01916. 
REFERENCES 
1 Bennett, T., Gardiner, S.M. and Kemp, P.A., An assess- 
ment of the effectiveness of neonatal treatment with guane- 
thidine as a means of producing sympathectomy, Br. J. 
Pharmacol., 76 (1982) 557-564. 
2 Blythe, T.H., Hall, R.C. and Hughes, I.E., An assessment 
of the cardiovascular sympathectomy induced by guanethi- 
dine, J. Pharm. Pharmacol., 28 (1976) 53-57. 
3 Burnstock, G., Evans, B., Gannon, B.J., Heath, J.W. and 
James, V., A new method of destroying adrenergic nerves 
in adult animals using guanethidine, Br. J. Pharmacol., 43 
(1971) 295-301. 
4 Chernow, B., Lake, R.C., Cruess, D., Coyle, J., Hughes, 
P., Balestrieri, F., Casey, L., Rainey, T.G. and Fletcher, 
J.R., Plasma, urine, and CSF catecholamine concentra- 
tions during and after ketamine anesthesia, Crit. Care 
Med., 10 (1982) 600-603. 
5 Evans, M.I., Halter, J.B. and Porte, D., Jr., Comparison 
of double- and single-isotope enzymatic derivative methods 
for measuring catecholamines in human plasma, Clin. 
Chem., 24 (1978) 657-662. 
6 Falck, B., Nielsen, K.C. and Owman, C., Adrenergic in- 
nervation of the pial circulation, Scand. J. Clin. Lab. In- 
vest., Suppl. 102, Sect. VI (1968) B. 
7 Friedman, R., Tassinari, L.M., Heine, M. and Iwai, J., 
Differential development of salt-induced and renal hyper- 
tension in Dahl hypertension-sensitive rats after neonatal 
sympathectomy, Clin. Exp. Hypertension, 1 (1979) 
779-799. 
8 Fuxe, K. and Ungerstedt, U., Localization of catechola- 
mine uptake in rat brain after intraventricular injection, 
Life Sci., 5 (1966) 1817-1824. 
9 Goldstein, D.S., Feuerstein, G., Izzo, J.L., Jr., Kopin, I.J. 
and Keiser, H.R., Validity and reliability of liquid chroma- 
tography with electrochemical detection for measuring 
plasma levels of norepinephrine and epinephrine in man, 
Life Sci., 28 (1981) 467-475. 
10 Grzanna, R. and Coyle, J.T., Absence of a relationship be- 
tween sympathetic neuronal activity and turnover of serum 
dopamine beta-hydroxylase, Naunyn-Schmiedeberg's 
Arch. Pharmacol., 304 (1978) 231-236. 
11 Hartman, B.K., Zide, D. and Udenfriend, S., The use of 
dopamine beta-hydroxylase as a marker for the central nor- 
adrenergic nervous system in rat brain, Proc. Natl. Acad. 
Sci. U.S.A., 69 (1972) 2722-2726. 
12 Heath, J.W., Evans, B.K., Gannon, B.J., Burnstock, G. 
and James, V.B., Degeneration of adrenergic neurons fol- 
lowing guanethidine treatment: an ultrastructural study, 
Virchow's Arch. Cell. Pathol., 11 (1972) 182-197. 
13 Holzwarth, M.A., Shinsako, J. and Dallman, M.F., Adren- 
al regeneration: time course, effect of hypothalamic hemi- 
islands and response to unilateral adrenalectomy, Neuroen- 
docrinology, 31 (1980) 168-176. 
14 Johnson, E.M. and O'Brien, F., Evaluation of the perma- 
nent sympathectomy produced by the administration of 
guanethidine to adult rats, J. Pharmacol. Exp. Ther., 196 
(1976) 53-61. 
15 Johnson, E.M., O'Brien, F. and Werbitt, R., Modification 
and characterization of the permanent sympathectomy pro- 
duced by the administration of guanethidine to newborn 
rats, Eur. J. Pharmacol., 37 (1976) 45-54. 
16 Kolka, M.A., Elizondo, R.S. and Weinberg, R.P., Sympa- 
thoadrenal responses to cold and ketamine anesthesia in 
the rhesus monkey, J. Appl. Physiol., 54 (1983) 896-900. 
17 Kopin, I.J., Lake, R.C. and Ziegler, M., Plasma levels of 
norepinephrine, Ann. Int. Med., 88 (1978)671-680. 
18 Kvetnansky, R., Weise, V.K., Nguyen, B.T. and Kopin, 
J., Effects of chronic guanethidine treatment and adrenal 
meduUectomy on plasma levels of catecholamines and cor- 
ticosterone in forcibly immobilized rats, J. Pharmacol. 
Exp. Ther., 209 (1979) 287-291. 
19 Lake, C.R., Gullner, H.G., Polinsky, R.J., Ebert, M.H., 
Ziegler, M.G. and Bartter, F.C., Essential hypertension: 
central and peripheral norepinephrine, Science, 211 (1981) 
955-957. 
20 Lake, C.R., Sternberg, D.E., van Kammen, D.P., Ball- 
enger, J.C., Ziegler, M.G., Post, R.M., Kopin, I.J. and 
Bunney, W.E., Jr., Schizophrenia: elevated cerebrospinal 
fluid norepinephrine, Science, 207 (1980) 331-333. 
264 
21 Levens, N.R., Peach, M.J. and Carey, R.M., Interactions 
between angiotensin peptides and the sympathetic nervous 
system mediating intestinal sodium and water absorption in 
the rat, J. Clin. Invest., 67 (1981) 1197-1207. 
22 Madison, R., Crutcher, K.A. and Davis, J.N., Sympatho- 
hippocampal neurons are inside the blood-brain barrier, 
Brain Research, 213 (1981) 183-189. 
23 McNicholas, L.F., Martin, W.R., Sloan, J.W. and Nozaki, 
M., Innervation of the spinal cord by sympathetic fibers, 
Exp. Neurol., 69 (1980) 383-394. 
24 Mefford, I.N., Ward, M.M., Miles, L., Taylor, B., Ches- 
hey, M.A., Keegan, D.L. and Barchas, J.D., Determin- 
ation of plasma catecholamines and free 3,4-dihydroxyphe- 
nylacetic acid in continuously collected human plasma by 
high performance liquid chromatography with electro- 
chemical detection, Life Sci., 28 (1981) 477-483. 
25 Moore, R.Y., Central catecholamine neuron systems: 
anatomy and physiology of the norepinephrine and epi- 
nephrine systems, Ann. Rev. Neurosci., 2 (1979) 113-168. 
26 Nielsen, K.C. and Owman, C., Adrenergic innervation of 
pial arteries related to the circle of Willis in the cat, Brain 
Research, 6 (1967) 773-776. 
27 Oldendorf, W.H., Brain uptake of radiolabeled amino 
amines and hexoses after arterial injection, Am. J. Physi- 
ol., 221 (1971) 1629-1639. 
28 Partanen, M., Linnoila, I., Hervonen, A. and Rapoport, 
S.I.,The effect of aging on extra-adrenal catecholamine 
storing cells of the rat, Neurobiol. Aging, 5 (1984) 105-110. 
29 Peuler, J.D. and Johnson, G.A., Simultaneous single iso- 
tope radioenzymatic assay of plasma norepinephrine, epi- 
nephrine, and dopamine, Life Sci., 21 (1977) 625-636. 
30 Popper, C.W., Chiueh, C.C. and Kopin, L.I., Plasma cate- 
cholamine concentrations in unanesthetized rats during 
sleep, wakefulness, immobilization, and after decapitation, 
J. Pharmacol. Exp. Ther., 202 (1977) 144-148. 
31 Post, R.M., Lake, C.R., Jimerson, D.C., Bunney, W.E., 
Jr., Wood, J.H., Ziegler, M.G. and Goodwin, F.K., Cere- 
brospinal fluid norepinephrine in affective illness, Am. J. 
Psychiat., 135 (1978) 907-912. 
32 Raskind, M.A., Peskind. E.R., Halter, J.B. and Jimerson, 
D.C., Norepinephrine and 3-methoxy-4-hydroxy pheny[ 
glycol in cerebrospinal fluid and plasma in Alzheimer's dis- 
ease, Arch. Gen. Psychiat. . 41 (1984)343-346. 
33 Reis, D.J. and Wurtman, R., Diurnal changes in brain nor- 
adrenalin, Life Sci., 7 (1968) 91--98. 
34 Skelton, F.R., Adrenal regeneration and adrenal-regener- 
ation hypertension, Physiol. Rev., 39 (1959) 162-182. 
35 Smith, B.H. and Sweet, W.H., Monoaminergic regulation 
of central nervous system function: 1. Noradrenergic sys- 
tems, Neurosurgery, 3 (1978) 109-119. 
36 Stein, L.J., Dorsa. D.M., Baskin, D.G., Figlewicz, D.P., 
Ikeda, H., Frankmann, S.P., Greenwood, M.R,C., Porte, 
D., Jr. and Woods, S.C., Immunoreactive insulin leyels are 
elevated in the cerebrospinal fluid of genetically obese 
Zucker rats, Endocrinology, 113 (1983) 2299-2301. 
37 Weil-Malherbe. H., Axelrod, J. and Tomchick, R., 
Blood-brain barrier for adrenaline, Science, 129 (1959) 
1226-1227. 
38 Wilkinson, C.W., Shinsako, J. and Dallman, M.F., Return 
of pituitary-adrenal function after adrenal enucleation or 
transplantation: diurnal rhythms and responses to ether, 
Endocrinology, 109 (1981) 162-169. 
39 Ziegler, M.G., Brooks, B.R., Lake, C.R,, Wood, J. and 
Enna, S.J., Norepinephrine and gamma-aminobutyric acid 
in amyotrophic lateral sclerosis, Neurology, 30 (1980) 
98-101. 
40 Ziegler, M.G., Lake, C.R., Wood, J.H., Brooks, B.R. and 
Ebert, M.H., Relationship between norepinephrine in 
blood and cerebrospinal fluid in the presence of a blood-ce- 
rebrospinal fluid barrier for norepinephrine, J. Neuro- 
chem., 28 (1977) 677-679. 
41 Ziegler, M.G., Lake, C.R., Wood, J.H. and Ebert, M.H., 
Norepinephrine in cerebrospinal fluid: basic studies, effects 
of drugs and disease. In J.H. Wood (Ed.), Neurobiology of 
Cerebrospinal Fluid, Plenum Press, New York, 1980, pp. 
141-152. 
